Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Antibacterial Effect of Bioceramic vs Calcium Hydroxide Medicaments in Root Canals

Official title: Antibacterial Efficacy of Bioceramic and Calcium Hydroxide-Based Intracanal Medicaments in Endodontic Treatment

Run by Medipol University · NCT07671326 · Data updated 2026-11-12

This study tests whether Bio-C Temp or UltraCal XS can better reduce bacteria inside root canals of lower molars with chronic apical periodontitis.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment24 (estimated)
SponsorMedipol University
Academic / other
Locations1 site (Istanbul, Istanbul)
StatusRecruiting
StartedOctober 15, 2025
Main results expectedSeptember 2026
Study endsDecember 2026
Registry record updatedJune 29, 2026
Trial IDNCT07671326 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 18–65 years with mandibular molars having chronic apical periodontitis and no systemic diseases, suitable for primary root canal treatment and rubber dam isolation.

Probably not a fit

Patients with systemic illness, recent antibiotic use, or teeth unsuitable for isolation may not benefit from the medicament comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial compares two intracanal medicaments, Bio-C Temp (bioceramic) and UltraCal XS (calcium hydroxide), in mandibular molars affected by chronic apical periodontitis. Bacterial load is measured before and after canal preparation, after medicament removal, and after final irrigation using droplet digital PCR. Procedures follow standard endodontic care with rubber dam isolation, chemomechanical preparation, and ultrasonic irrigation; samples are collected at defined points to assess antimicrobial effectiveness. Participants are adults 18–65 years, systemically healthy, requiring primary root canal treatment and presenting periapical radiolucency. The study is conducted at Istanbul Medipol University, under Medipol University as lead sponsor.

Why it matters

Potential benefit: If successful, patients may experience better reduction of intracanal bacteria, potentially improving healing and treatment outcomes.

How similar studies have gone: Previous studies have explored intracanal medicaments, with bioceramics showing promising antimicrobial effects in some settings, but direct head-to-head clinical evidence remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged between 18 and 65 years
* Being systemically healthy (ASA I or ASA II)
* Mandibular molar teeth with a radiographically detectable radiolucent lesion in the periapical region
* Willingness of the volunteer or their legal representative to participate in the study by signing the Informed Consent Form

Exclusion Criteria:

* Patients who have received antibiotics or corticosteroids within the last 3 months
* Patients with systemic diseases
* Teeth that cannot be properly isolated with a rubber dam
* Teeth with periodontal pockets \>4 mm and teeth with crown/root fractures
* Individuals who are undergoing or planning to start orthodontic treatment during the study period
* Pregnant or breastfeeding individuals

Where it's running

  • Istanbul Medipol University
    Istanbul, Istanbul, Turkey (Türkiye)
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.